Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Virginia Health System, Charlottesville, Virginia

Virginia Commonwealth University, Richmond, Virginia